Markets
Sofi Surges on Student Loan limits in Senate Bill
(CSA Archives/Getty Images)

SoFi adds to recent run, hits record high close

The stock has doubled over the last three months.

Matt Phillips
8/25/25 3:13PM

SoFi Technologies jumped 4.5% on the day to finish Monday at a record closing price of $26.15, topping the previous high-water mark set back in early 2021.

SoFi’s gains Monday did not come in the context of a broad market rise and there was little solid news on the fintech firm that might account for the move, other than continued signs that SoFi is garnering its fair share of retail trader attention — call options buying on Friday and Monday were roughly double the average over the previous 20 days.

That attention makes sense: SoFi has staged a remarkable turnaround this year.

It was down nearly 40% for the year in early April, roughly twice the loses of the Nasdaq Composite. But since hitting a 2025 low on April 8, the stock is up more than 175%.

Some of the turnaround is fundamental, as the company posted better-than-expected earnings in Q1 and Q2, garnering analyst upgrades to earnings expectations and share price targets.

Helpful background music in Washington also seems to be playing a role. The GOP budget bill President Trump signed into law last month will reduce federal student lending, likely pushing more borrowers toward private lenders like SoFi.

Meanwhile, SoFi’s return to the world of crypto trading, which it initially announced back in June, and plans to eventually issue stablecoins are just the kind of thing to provide a stock price with a bit of pop in the current, and arguably frothy, market environment.

More Markets

See all Markets
markets

Hims rises, Novo dips after FDA releases “green list” of GLP-1 raw material suppliers

Hims & Hers rose and Novo Nordisk slipped in early trading after the US Food and Drug Administration released a "green list" of foreign GLP-1 ingredient suppliers that it considers in compliance with agency standards.

Some telehealth companies like Hims sell copycat versions of Novo's and Eli Lilly’s blockbuster weight-loss drugs through compounding pharmacies, which take the active ingredients from FDA-approved medications and make adjusted, or "personalized,” versions of the drug for patients.

Novo and Lilly have fought against this, arguing that it infringes on their intellectual property. They've sued smaller telehealth providers, pharmacies, and clinics in lieu of any action against them from the FDA. Instead, the FDA gave compounders a list of suppliers it deems safe.

Recent developments in the cases filed by the drugmakers so far as well as the FDA's recent actions suggest telehealth companies may be in a less risky position than investors previously thought. As of Monday morning, prediction markets pegged the likelihood of a suit from Novo against Hims at 34%, down from about 70% earlier this month.

markets

UNH rises after saying it plans to reiterate outlook

UnitedHealth rose 2% in early trading after it disclosed that it plans to reiterate its full-year earnings outlook when it meets with investors this week.

The company said on July 29 that it was expects to report annual adjusted earnings per share of at least $16. The company had previously pulled full-year guidance and prior to that withdrawal, had told investors it expected to see earnings of $26 to $26.50 per share.

Currently, a analysts polled by FactSet are penciling in $16.23, compared to $17.21 before the guidance came down.

UnitedHealth has had a tumultuous year as he industry has been hit with rising costs of care, and UnitedHealth specifically has been hit with investigations into its Medicare Advantage practices. It recently got a boost after Warren Buffett's Berkshire Hathaway revealed that it's built a stake in the company

markets

T-Mobile and other wireless carriers tumble on SpaceX’s purchase of spectrum licenses from EchoStar

T-Mobile is the worst-performing S&P 500 constituent in early trading, off 5.2% as of 8:27 a.m. ET.

The reason why? SpaceX purchased a pair of spectrum licenses from EchoStar for roughly $17 billion, and as such, SpaceX might no longer need to rely as heavily on T-Mobile going forward.

In August 2022, T-Mobile and SpaceX announced a partnership in which the carrier would help SpaceX’s Starlink provide mobile connectivity from space. The first such satellites launched in January 2024, and T-Mobile ran an ad during the 2025 Super Bowl touting a beta trial of Starlink-powered satellite texting.

However, other wireless providers like AT&T and Verizon are also down (4.5% and 4.2%, respectively) ahead of the open, so this may also simply be a selloff linked to the wireless providers not being the ones to purchase these valuable spectrum licenses themselves — even though AT&T struck a deal with EchoStar in late August to purchase $23-billion in spectrum assets.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.